NasdaqGM:NTLABiotechs
Intellia Therapeutics (NTLA) Could Be 50% Undervalued After Its Q2 2026 Earnings
Intellia Therapeutics (NTLA) reported Q2 2026 results that kept the company in loss making territory, although the net loss and loss per share for both the quarter and first half improved versus last year.
See our latest analysis for Intellia Therapeutics.
Intellia Therapeutics’ latest earnings release on 6 August came after a period where the stock’s year to date share price return of 30.51% is set against a 1 year total shareholder return of 11.92% and a 3 year total shareholder return that...